• The total cost of treating BCG-refractory patients with Cis with valrubicin is approximately 27% higher than treating them with cystectomy. (Note: This estimate differs from the 45% value reported in the abstract due to updates performed on the model since the time of abstract submission.)
model had been previously described and validated. 17 We compared the current model's results also to epidemiology studies identifi ed by Kulkarni et al. 17 • The lifetime cost per person of treating patients with HR Ta/ T1 with BCG used fi rst-line and second-line (£36,349) was 27% higher (20% in the abstract) than comparable costs (£28,710 [CAN$42,400, 2005 , infl ated to 2013, and converted to British pounds using a factor of 0.59.]) estimated by Kulkarni et al., 2 who also used a similar treatment pathway. This difference is due to the inclusion of costs of managing 15 adverse events (£6,289) in the present model.
• The model estimates of survival and quality-adjusted survival per person with HR Ta/T1 treated with BCG (11.1 years and 10.3 quality-adjusted life-years [QALYs]) were within 5% and 10% of that reported in Kulkarni et al.
2
(10.6 years and 9.39 QALYs).
• The model estimates a 5-year overall survival rate of approximately 80% for patients with HR Ta/T1 treated with BCG, and this is comparable to the 83% 5-year overall survival rate reported in Lamm et al.
18
The model estimates a 44% overall survival rate at 15 years, which is somewhat higher than the 37% overall survival rate reported in Cookson et al. 19 Kulkarni et al. 17 also compared their estimates of overall survival against these studies.
CONCLUSION
• This model can be used to estimate costs and health outcomes associated with existing treatment strategies as well as the cost-effectiveness of novel intravesical therapies.
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FUNDING
This work was funded in part by Telormedix. The guidelines defi ne high-risk (HR) NMIBC to include the following: Cis; T1 tumors; and a subset of Ta tumors (described as "HR Ta")-specifi cally, those that are grade 3 (G3) or are multiple, recurrent, large (> 3 cm) G1 and/or G2 tumors. This heterogeneous presentation results in patient subpopulations with diverse treatment requirements.
CONTACT INFORMATION
• Current health economic models for NMIBC have the following limitations: (1) they focus only on a single NMIBC subpopulation 2, 3 ; (2) they do not cover all relevant treatment options [2] [3] [4] ; and/or (3) they are not specifi c to HR NMIBC. 3, 4 • The objective of this study was to develop a comprehensive model to estimate costs and health outcomes with various HR NMIBC treatment strategies for a variety of patient subpopulations.
METHODS
• In Microsoft Excel, we programmed a Markov model (Figure 1 ) to estimate the costs and health outcomes associated with the treatment of patients with HR NMIBC based on published European and United States (US) treatment guidelines.
1,5
The model, which employs a 3-month cycle and runs over a lifetime time horizon, takes a United Kingdom (UK) payer perspective.
• The model considers three patient populations according to tumor type: Cis, HR Ta/T1, and concomitant Cis + Ta/T1 NMIBC.
• In addition to trans-urethral resection of the bladder tumor (TURBT), applicable for Ta and T1 tumors, the model considers intravesical therapy with bacillus CalmetteGuerin (BCG) and mitomycin C (MMC) as fi rst-and/or second-line or as alternative treatments for patients refractory to or intolerant of fi rst-and/or second-line treatment.
-Valrubicin, although not approved for use in the UK, was included in the model for use in BCG-refractory patients with Cis, according to its package insert in the US.
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• The goals of intravesical therapy include delaying or avoiding recurrence of NMIBC.
• A cohort of patients enters the model upon diagnosis of HR NMIBC and receives a fi rst-line intravesical therapy (adjunctive to TURBT or as monotherapy, as applicable). If the tumor is refractory to or the patient is intolerant of the fi rst-line intravesical therapy (established within the fi rst 6 months [2 cycles] of use), the patient receives the alternative fi rst-line therapy if an alternative therapy has been selected. Otherwise, the patient moves directly to cystectomy.
-In the case of refractoriness to/intolerance of an alternative therapy, the patient moves directly to cystectomy.
• Patients who move into the "Sustained tumor free (fi rstline)" health state but who eventually experience a recurrence receive second-line therapy (which may be the same or different from the fi rst-line therapy) if a secondline has been selected. Otherwise, the patient moves directly to cystectomy.
-In the case of refractoriness to/intolerance of second-line therapy, the patient moves directly to cystectomy.
-Patients who move into the "Sustained tumor free (secondline)" health state but who eventually experience a recurrence move directly to cystectomy.
• Transition probabilities (based on response rates and recurrence rates among responders for Cis, and based on recurrence rates for HR Ta/T1), adverse event rates, resource use, unit costs, and utilities were estimated based on published literature and/or publicly available data.
• The model was validated against published epidemiology and cost data. 
Key Model Assumptions
• The effi cacy of an intravesical treatment in preventing muscle invasion is linked to its effi cacy at preventing recurrence.
• With the exception of muscle invasion, recurrence is of the same grade and stage as at model entry.
Key Model Inputs
Intravesical Therapy Administration and Safety/Tolerability
• Table 1 presents the intravesical therapy induction and maintenance regimens.
• Adverse event rates and rates of discontinuation due to intolerance to intravesical treatment were obtained from Bohle et al.
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The adverse event rates were distributed by grade for BCG and MMC, based on Lamm et al. 8 The valrubicin adverse event rates were distributed by grade according to the MMC proportions.
Intravesical Therapy Effi cacy
• For each intravesical therapy when used at each line, the rates of insuffi cient response (for patients with Cis [ Table 2 ]) and recurrence (among responders with Cis [ Table 3 ] and among patients with HR Ta/T1 [ Table 4 ]) were standardized to a follow-up period of 6 months (insuffi cient response) or 2 years (recurrence) and then converted into cycle-specifi c transition probabilities by fi tting a geometric distribution to the standardized insuffi cient response and/or recurrence rates.
• Effi cacies in patients with concomitant Cis + Ta/T1 are assumed equal to effi cacies in patients with Cis.
Risks of Metastasis and Death
• The model assumed an average cohort age of 60 years, 77.6% male.
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Average life expectancy of males and females in England and Wales at 60 years was estimated as 79.90 years and 83.32 years, respectively, from the UK Offi ce for National Statistics.
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Risk of death was adjusted to refl ect acute postoperative (cystectomy) risk and in the case of muscle-invasion and metastasis (Table 5) .
Costs and Utilities
• TURBT plus one follow-up physician visit post-TURBT was assumed for patients with HR Ta/T1 or concomitant Cis + Ta/ T1. The unit costs for a TURBT and a follow-up visit were £1,745.00 and £94.00.
15 Table 6 presents costs of intravesical therapy.
• Resources assumed to be used to treat adverse events were reviewed with a clinical advisor. Unit costs associated with resources used to treat adverse events were obtained from the UK's Personal Social Services Research Unit (PSSRU) for 2013.
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RESULTS
• We present results from some key scenario analyses (Table 8 ).
• Baseline utility (from which are deducted disutilities for treatment and treatment-related adverse events, as applicable) is assumed to be 1; utility of death is assumed to be 0.
• Disutility from TURBT, -0.10, is from Kulkarni et al.
2
and is applied for 1 day.
• Intravesical therapy disutilities for MMC and valrubicin are assumed to be the same as BCG, -0.02, from Kulkarni et al.
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Intravesical therapy disutilities are applied for one day for each day of intravesical administration.
• Table 7 presents health state costs and utilities associated with cystectomy, postcystectomy, muscle-invasion, and metastasis.
